Myeloid malignancies


The heterogeneous disorders characterized by uncontrolled proliferation and/or blockage of differentiation of abnormal myeloid progenitor cells have received a lot of diversified attention through general sessions such as plenary and education sessions but also via more focused presentations such as the Science-in-Focus sessions.

The highlights are the laboratory diagnostics talk on using NGS technologies to improve AML care from Torsten Haferlach, Epigenomic changes: Implications for prevention, interception and therapy by Steve Baylin and deciphering the role of RUNX1 isoforms in the development of transient abnormal myelopoiesis by Sofia Gialesaki.

Links to the library and multimedia

Click on the blocks below to read the full stories, view abstracts, presentations, webcasts and expert interviews.

Torsten Haferlach | NGS technologies in AML: Time to use in clinical care?

Stephen Baylin | Epigenomic changes mediating leading risk scenarios for initiation and progression of cancers. Implications for prevention, interception and therapy

Sofia Gialesaki | Deciphering the role of RUNX1 isoforms in the development of transient abnormal myelopoiesis

Gert Ossenkoppele | Clinical value of the new AML drugs

Alan List | The role of innate immunity in MDS pathogeneis

Prithviraj Bose | SOTATERCEPT (ACE-011) in subjects with MPN-associated myelofibrosis and anemia

Eva Hellström- Lindberg | Is iron chelation really necessary in MDS?

Shahram Kordasti | Immune side of MDS

Herman Einsele | CAR-T cells in MM

Fred Falkenburg | Targeting leukemia with HLA class II restricted T cells

Irene Roberts | Neonatal leukemia